Peptides · Peptide comparison
Cetrorelix vs Ganirelix
Fast-acting GnRH antagonist that stops premature ovulation during IVF cycles
Fast-acting GnRH antagonist that stops premature ovulation during fertility treatment
- Hormone Support
- Hormone Support
At a glance
Quick comparison
Dose rangeCetrorelix3–3 mgGanirelix250–250 mcg
FrequencyCetrorelixOnce dailyGanirelixOnce daily
AdministrationCetrorelixSubcutaneous injectionGanirelixSubcutaneous injection
Cycle lengthCetrorelixOngoing/indefiniteGanirelixOngoing/indefinite
Onset speedCetrorelixModerate (1-2 weeks)GanirelixModerate (1-2 weeks)
Evidence levelCetrorelixStrong human trials (Phase 3 or FDA approved)GanirelixStrong human trials (Phase 3 or FDA approved)
Efficacy
Benefit ratings
Ovulation Control
Cycle Flexibility
Side Effect Profile
IVF Success Improvement
Safety & OHSS Prevention
Technical data
Compound specifications
Cetrorelix
- Molecular formula
- C70H92ClN17O14
- Molecular weight
- 1431.06 Da
- Half-life
- Approximately 2-6 hours (varies by route of administration)
- Bioavailability
- ~85% (subcutaneous injection)
- CAS number
- 100885-89-0
Ganirelix
- Molecular formula
- C80H113ClN18O13
- Molecular weight
- 1570.4 g/mol
- Half-life
- 12.8 hours after a single dose; 16.2 hours at steady state
- Bioavailability
- ~91% (subcutaneous injection)
- CAS number
- 124904-93-4
Protocols
Dosing compared
Cetrorelix
Subcutaneous
- 0.25 mgOnce every 24 hours · From stimulation day 5-6 until the day of hCG (about 4-9 days)The FDA-approved multiple-dose plan. A 0.25 mg shot under the skin each day stops an early LH surge during fertility (IVF) ovarian stimulation. [5]
- 3 mgSingle dose (one injection) · One dose covers at least 4 days; add 0.25 mg daily after if hCG is delayedThe FDA-approved single-dose plan. One 3 mg shot is given when estrogen levels show the follicles are ready (usually stimulation day 7). It protects against an early LH surge for at least 4 days. [5][6]
Ganirelix
Subcutaneous
- 250 mcgOnce daily during the mid-to-late follicular phase · Continued daily until the day of hCG administration (typically about 5-9 days)FDA-labeled dose for inhibiting premature LH surges during controlled ovarian stimulation; started after several days of FSH and continued until hCG trigger [4].
Applications
Best suited for
Cetrorelix
- Planning IVF with precise ovulation timing
- Cetrorelix is particularly well-suited for individuals focused on planning ivf with precise ovulation timing. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Preventing premature egg release during controlled stimulation
- Cetrorelix is particularly well-suited for individuals focused on preventing premature egg release during controlled stimulation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Managing polycystic ovary syndrome (PCOS) during fertility treatment
- Cetrorelix is particularly well-suited for individuals focused on managing polycystic ovary syndrome (pcos) during fertility treatment. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Ganirelix
- Improving IVF or ICSI success rates
- Ganirelix is particularly well-suited for individuals focused on improving ivf or icsi success rates. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Preventing premature ovulation during egg retrieval cycles
- Ganirelix is particularly well-suited for individuals focused on preventing premature ovulation during egg retrieval cycles. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Controlling ovarian stimulation in women with unpredictable cycles
- Ganirelix is particularly well-suited for individuals focused on controlling ovarian stimulation in women with unpredictable cycles. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Safety profile
Side effects
Cetrorelix
Common
- Injection site reactions (redness, itching, swelling)
- Headache
- Nausea
- Mild abdominal discomfort
- Dizziness
- Allergic reactions (rash, difficulty breathing)
- Ovarian hyperstimulation syndrome (OHSS) if used with other fertility drugs
- Ovarian cysts
- Vaginal bleeding
- Mood changes
- Liver enzyme changes
- Pelvic pain
- Severe allergic reaction
Serious
- Severe allergic reaction
Ganirelix
Common
- Mild discomfort at treatment site
- Injection site reactions (redness, bruising, swelling)
- Headaches
- Abdominal pain
- Pelvic discomfort
- Nausea
- Fatigue or dizziness
Serious
- Severe allergic reaction
Research status
Safety & evidence
Cetrorelix
- Evidence level
- Strong human trials (Phase 3 or FDA approved)
- FDA status
- FDA approved for this use
- Safety overview
- Cetrorelix is an FDA-approved GnRH antagonist used exclusively in assisted reproductive technology with proven safety in short-term reproductive cycles. Unlike GnRH agonists, cetrorelix lacks the initial testosterone flare, making it well-tolerated for ovarian stimulation. Primary side effects are mild and local—injection site reactions (erythema, bruising) occur in 10-20% of patients. No systemic bone loss, cardiovascular complications, or serious adverse events have been reported in the reproductive context where treatment duration is limited (typically 7-10 days). The short treatment window in IVF protocols minimizes long-term safety concerns. Hypersensitivity reactions are rare but possible.
Contraindications
- Known allergy to cetrorelix or any ingredient
- Pregnancy (it may harm the developing baby)
- Undiagnosed vaginal bleeding
- Severe liver or kidney disease
- Latex allergy (some syringes contain latex)
Ganirelix
- Evidence level
- Strong human trials (Phase 3 or FDA approved)
- FDA status
- FDA approved for this use
- Safety overview
- Ganirelix is an FDA-approved GnRH antagonist whose safety was evaluated in 794 women in two controlled clinical trials, with treatment lasting 1–14 days. [4] Adverse events were infrequent: gynecological abdominal pain 4.8%, headache 3.0%, ovarian hyperstimulation syndrome 2.4%, vaginal bleeding 1.8%, and injection site reactions and nausea 1.1% each. [4] Hypersensitivity reactions, including anaphylaxis, angioedema and urticaria, have been reported after marketing, sometimes with the first dose; the needle shield on some syringes contains natural rubber latex. [4] Because it blocks the GnRH receptor directly, it causes no initial release of gonadotropins. [4]
Contraindications
- Known or suspected pregnancy [4]
- Known hypersensitivity to ganirelix or any of its components, including the natural rubber latex needle shield on some syringes [4]
- Known hypersensitivity to GnRH or any other GnRH analog [4]
- Ovarian cysts larger than 3cm
Decision guide
Which is right for you?
Cetrorelix
Choose Cetrorelix if…
- Planning IVF with precise ovulation timing
- Preventing premature egg release during controlled stimulation
- Managing polycystic ovary syndrome (PCOS) during fertility treatment
Ganirelix
Choose Ganirelix if…
- Improving IVF or ICSI success rates
- Preventing premature ovulation during egg retrieval cycles
- Controlling ovarian stimulation in women with unpredictable cycles